North America, the largest and most attractive pharma markets globally, is a strategic geography for Strides. Our presence there enhances our ability to reach a larger base of customers and patients in need of quality treatment options. Strides Pharma Inc. is the front-end company with a clear vision of providing quality healthcare products to the market both in Prescription, OTC and consumer health markets.

Strides re-entered the US market in 2015 post the divestment of our Specialty injectables Franchisee- Agila. Today, we are on the cusp of getting to a critical size and our focus is mainly on niche, low volume, low competition, high technology barrier products built around Modified Releases, soft-gel capsules (SGCs), topicals and liquids. We also produce high competition products where enjoy the benefits of a fully integrated value chain. We have an overwhelming focus on an efficient R&D to derive on time approvals, market launches and sustain growth momentum. In the Consumer Healthcare space, we operate both in Brands as well as Private Labels and our key brands include JointFlex®, Vanquish®, Pediacare® and Fergon®.

At the end of March 2018, we have a portfolio of 74 filed ANDAs (with 30 pending approvals). Going forward, we will utilise our R&D capabilities for 15-20 filings every year to benefit from new regulations. Additionally, we will we will also leverage our front-end presence to scale our business.